Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

Video content above is prompted by the following:

• Abemaciclib is recommended by NCCN in this setting based on the monarchE trial, which recently released its 5-year long-term data in January.
  • Describe the updated survival data, including both invasive disease-free survival and overall survival. How have these survival rates evolved with each annual analysis?
  • Please highlight the follow-up time of patients.
• Are there specific subgroups of patients within the monarchE trial who derived particular benefit from the addition of abemaciclib?